What is porphyria?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Porphyria?

Porphyrias are a group of rare inherited metabolic disorders caused by deficiencies in specific enzymes of the heme biosynthesis pathway, resulting in toxic accumulation and excretion of porphyrins and their precursors (δ-aminolevulinic acid and porphobilinogen), which manifest clinically as acute neurovisceral attacks and/or cutaneous photosensitivity depending on which enzyme is deficient. 1

Pathophysiology

  • The disorders result from abnormal functioning of enzymes in the heme biosynthetic pathway, causing accumulation of specific metabolites upstream of the enzymatic defect 1
  • In acute hepatic porphyrias, neurotoxic precursors (particularly δ-aminolevulinic acid and porphobilinogen) accumulate and cause neurological damage 2, 3
  • In cutaneous porphyrias, porphyrins accumulate in the skin and react with light, causing photosensitivity in sun-exposed areas 3, 4

Classification by Clinical Presentation

Acute Neurovisceral Porphyrias

  • Acute Intermittent Porphyria (AIP): Most common acute porphyria, autosomal dominant inheritance, presents with abdominal pain and neurological symptoms 1, 2
  • Variegate Porphyria (VP): Autosomal dominant, can present with both neurovisceral attacks and cutaneous symptoms 1, 3
  • Hereditary Coproporphyria (HCP): Autosomal dominant, similar to VP with both potential manifestations 1, 3
  • ALA-dehydratase Deficiency Porphyria: Autosomal recessive, extremely rare with only six documented cases 1, 5

Cutaneous Porphyrias

  • Porphyria Cutanea Tarda (PCT): Most common porphyria overall, usually sporadic (non-hereditary) in most populations, presents with bullous skin lesions 1, 2
  • Erythropoietic Protoporphyria (EPP): Autosomal recessive, causes acute painful photosensitivity without scarring, often presents in childhood 1, 2
  • Congenital Erythropoietic Porphyria (CEP): Autosomal recessive, severe bullous skin lesions and hemolytic anemia, often evident in newborns 1
  • X-linked Erythropoietic Protoporphyria (XLEPP): X-linked inheritance, acute painful photosensitivity 1

Clinical Manifestations

Acute Neurovisceral Symptoms

  • Severe abdominal pain (most common presenting symptom), nausea, vomiting, constipation 2, 3
  • Neuropsychiatric symptoms including confusion, anxiety, hallucinations, and in severe cases, seizures and psychosis 3, 6
  • Peripheral neuropathy (motor-predominant, axonal) that can progress to paralysis and respiratory failure if untreated 3, 6
  • Autonomic dysfunction with tachycardia, hypertension, and hyponatremia 2, 3
  • 90% of symptomatic patients are women, with attacks rare before menarche or after menopause 2
  • 90% of patients experience only one or few attacks in their lifetime 2

Cutaneous Symptoms

  • Bullous skin lesions with skin fragility on sun-exposed areas (PCT, VP, HCP, CEP) 1, 3
  • Acute painful photosensitivity without scarring (EPP, XLEPP) 1, 2

Age of Onset

  • Erythropoietic porphyrias (CEP, EPP) often present in newborns or children 1
  • Acute porphyrias (AIP, VP, HCP) typically become symptomatic in early adulthood 1
  • PCT most often presents in adults or older age 1

Long-Term Complications

  • Liver disease including primary liver cancer and acute liver failure 1, 2
  • Chronic kidney disease and renal failure 1, 2
  • Hypertension, osteoporosis, vitamin D deficiency, and anemia 1, 2

Genetic Considerations

  • Most porphyrias are hereditary with autosomal dominant, autosomal recessive, or X-linked inheritance patterns 1
  • Critical caveat: Autosomal dominant porphyrias have low clinical penetrance—pathogenic variants are frequently found in the general population without causing metabolic or clinical disease 1
  • PCT is predominantly a sporadic, non-hereditary disease in most populations 1
  • Genetic testing has limited diagnostic value in symptomatic patients and should not be used for screening without prior biochemical confirmation 1, 2

Prevalence

  • All forms combined affect fewer than 200,000 people in the United States 5
  • PCT: approximately 1 in 10,000 (most common) 5
  • AIP: approximately 1 in 20,000 (most common acute porphyria) 5
  • EPP: approximately 1 in 50,000 to 75,000 5
  • CEP: approximately 1 in 1,000 or less (extremely rare) 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Porfirias: Trastornos Metabólicos Raros de la Biosíntesis del Heme

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Porphyria: What Is It and Who Should Be Evaluated?

Rambam Maimonides medical journal, 2018

Research

Management of acute and cutaneous porphyrias.

International journal of clinical practice, 2002

Research

Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias.

Current protocols in human genetics, 2015

Research

Porphyria and its neurologic manifestations.

Handbook of clinical neurology, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.